Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02065570 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease
A Phase 3 study of Crohn's Disease, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 514
- Enrollment target
- 20
- Study locations
NCT02065570 is a Phase 3 study of Crohn's Disease that has completed, run by AbbVie. The registered enrollment target is 514 participants, below the 2,390-participant average among 105 other Crohn's Disease trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT02065570, a Phase 3 study of Crohn's Disease, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 514 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate higher versus standard adalimumab dosing regimens for induction and maintenance therapy in subjects with moderately to severely active Crohn's Disease and evidence of mucosal ulceration.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Adalimumab
Study Locations (20)
Florida
- Gastroenterology Group Naples /ID# 122493 - Naples
- Internal Med Specialists /ID# 137737 - Orlando
- Shafran Gastroenterology Ctr /ID# 119057 - Winter Park
Georgia
- Winship Cancer Institute of Emory University /ID# 136851 - Atlanta
- Atlanta Gastro Assoc /ID# 119065 - Atlanta
- Gastroenterology Associates of Central Georgia, LLC /ID# 119056 - Macon
Illinois
- Northwestern University Feinberg School of Medicine /ID# 119043 - Chicago
- University of Chicago DCAM /ID# 119077 - Chicago
- Carle Foundation Hospital Digestive Health Research Center /ID# 136008 - Urbana
Alabama
- Birmingham Gastroenterology Associates O.C /ID# 137282 - Birmingham
- Digestive Health Specialists of the Southeast /ID# 122483 - Dothan
California
- Moore UC San Diego Cancer Center /ID# 119053 - La Jolla
- Axis Clinical Trials /ID# 130390 - Los Angeles
Maryland
- Investigative Clinical Research /ID# 119033 - Annapolis
- MGG Group Co, Inc.Chevy Chase Clinical Research /ID# 119042 - Chevy Chase
Colorado
- Rocky Mountain Gastroenterology /ID# 119038 - Wheat Ridge
Connecticut
- Medical Research Ctr CT /ID# 119037 - Hamden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 514 participants |
| Start Date | 2014-05-01 |
| Est. Completion | 2020-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02065570
The ClinicalTrials.gov registry entry for NCT02065570 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 514 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,390-participant average among 105 other Crohn's Disease trials with a reported enrollment target (78% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02065570 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT02065570 about?
NCT02065570 is a clinical study titled "Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease". This study will evaluate higher versus standard adalimumab dosing regimens for induction and maintenance therapy in subjects with moderately to severely active Crohn's Disease and evidence of mucosal ulceration.
What is the current status of trial NCT02065570?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 514 participants. The study started on 2014-05-01. Estimated completion is 2020-01-30.
What conditions does trial NCT02065570 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT02065570?
The interventions under investigation include: Placebo (DRUG), Adalimumab (DRUG).
Who is sponsoring clinical trial NCT02065570?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02065570 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.